Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 3/20 | 0.49 |
| ▸ | FLT3 | P36888 | 2/20 | 0.49 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.46 |
| ▸ | JAK1 | P23458 | 3/20 | 0.46 |
| ▸ | CAMK2D | Q13557 | 3/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.44 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.44 |
| ▸ | CDK2 | P24941 | 1/20 | 0.44 |
| ▸ | CDK9 | P50750 | 1/20 | 0.44 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.44 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.44 |
| ▸ | FYN | P06241 | 4/20 | 0.43 |
| ▸ | CDC7 | O00311 | 1/20 | 0.43 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.43 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15208070 | 0.95 | SYK (0.50) | SYKFLT3PTK2JAK1CAMK2D | |
| SCHEMBL15207564 | 0.90 | PTK2 (0.50) | SYKPTK2JAK1CAMK2DCCNT1 | |
| SCHEMBL20941 | 0.85 | FYN (0.51) | SYKPTK2MAPK8FYNJAK2 | |
| SCHEMBL21149 | 0.83 | SYK (0.46) | SYKFYN | |
| SCHEMBL15207265 | 0.82 | MAP4K4 (0.42) | SYKJAK1MAP4K4JAK2 | |
| SCHEMBL21230 | 0.78 | KDR (0.43) | SYKJAK2 | |
| SCHEMBL20010 | 0.77 | KDR (0.52) | SYKTP53JAK2 | |
| SCHEMBL15207171 | 0.76 | KDR (0.41) | SYKPTK2JAK2 | |
| SCHEMBL3213399 | 0.75 | JAK1 (0.64) | PTK2JAK1JAK2 | |
| SCHEMBL20253 | 0.74 | KDR (0.54) | SYKPTK2TP53JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2609098-B1 | TRIAZOLOPYRAZINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2016-07-13 | — | — | EP | disclosed |
| US-9023851-B2 | Triazolopyrazine derivatives | MERCK PATENT GMBH (DE) | 2015-05-05 | — | — | US | disclosed |
| US-9023851-B2 | Triazolopyrazine derivatives | MERCK PATENT GMBH (DE) | 2015-05-05 | — | — | US | disclosed |
| US-20130225568-A1 | TRIAZOLOPYRAZINE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-08-29 | — | — | US | disclosed |
| US-20130225568-A1 | TRIAZOLOPYRAZINE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-08-29 | — | — | US | disclosed |
| EP-2609098-A1 | TRIAZOLOPYRAZINE DERIVATIVES | Merck Patent GmbH (DE) | 2013-07-03 | — | — | EP | disclosed |
| WO-2012025186-A1 | TRIAZOLOPYRAZINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2012-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225568-A1 | TRIAZOLOPYRAZINE DERIVATIVES | SYK, IRAK1, ZAP70 | SYK 1/4885FLT3 16/4885PTK2 367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.